GlobeNewswire Inc.··Moonlake ImmunotherapeuticsMoonLake's Sonelokimab Sustains Strong Phase 3 Results in Hidradenitis Suppurativa
MoonLake reports Week 40 Phase 3 data for sonelokimab showing 62% HiSCR75 response rates in hidradenitis suppurativa with no new safety signals.
MLTXPhase 3 clinical trialquality of life